FTSV News and Press, Forty Seven Inc. From 03/10/20

It's hard to swim against the current. But it's not impossible to do so. Most stocks have fallen hard in the current market correction that was initially caused by worries about the coronavirus and is now being worsened by plunging oil prices. There are exceptions, though. Three profitable heal...

Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies - FTSV, GCAP, ETFC NEW YORK, NY / ACCESSWIRE / March 9, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair ...

NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning th...

Gilead Sciences ( GILD ) acquired Forty Seven Inc. ( FTSV ) and paid a total of $4.8 billion to do so . Gilead has continued to do well when it comes to its HIV franchise, but faced significant challenges in other areas like its NASH pipeline. I believe that buying Forty Seven was a sma...

March's trading is off to a volatile start following the substantial sell-off that took place at the end of February. The novel coronavirus officially known as SARS-CoV-2 continues to dominate headlines and cast uncertainty over the global economic outlook. The situation's progression will likel...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Gilead Sciences (NASDAQ: GILD) is in discussions with cancer biotech Forty Seven (NASDAQ: FTSV) about a possible takeover or partnership, according to an article published Thursday by Bloomberg . According to the report, no deal has been finalized, and Forty Seven has received interest ...

Dynatronics (NASDAQ: DYNT ) +224% . More news on: Dynatronics Corporation, Altimmune, Inc., Allied Healthcare Products, Inc., Stocks on the move, , Read more ...

Gilead Sciences (NASDAQ: GILD) is reportedly in buyout, or possible licensing, talks with the clinical-stage cancer company Forty Seven (NASDAQ: FTSV) , according to Bloomberg. Forty Seven's lead drug candidate, magrolimab , targets a fairly unique therapeutic pathway named CD47. By inhi...

Forty Seven Inc. (NASDAQ: FTSV ) +23% after-hours following a Bloomberg report that Gilead Sciences (NASDAQ: GILD ) has approached the company with a takeover offer . More news on: Forty Seven, Inc., Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Merger & acquisi...